\BOOKMARK [1][-]{section.0.1}{Problemafgr\346nsning}{}% 1
\BOOKMARK [2][-]{subsection.0.1.1}{Problemformulering}{section.0.1}% 2
\BOOKMARK [0][-]{chapter.1}{Beskrivelse og tekniske karakteristika for teknologien \(TEC\)}{}% 3
\BOOKMARK [1][-]{section.1.1}{Form\345l}{chapter.1}% 4
\BOOKMARK [1][-]{section.1.2}{HTA sp\370rgsm\345l}{chapter.1}% 5
\BOOKMARK [1][-]{section.1.3}{Metode}{chapter.1}% 6
\BOOKMARK [1][-]{section.1.4}{Teknologiens egenskaber}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.4.1}{Fokusomr\345de for QST}{section.1.4}% 8
\BOOKMARK [2][-]{subsection.1.4.2}{Unders\370gelse af PPT, TSP og CPM}{section.1.4}% 9
\BOOKMARK [1][-]{section.1.5}{Teknologiens begr\346nsninger}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.5.1}{Begr\346nsende faktorer ved benyttelse af QST}{section.1.5}% 11
\BOOKMARK [1][-]{section.1.6}{Sammenligning med nuv\346rende metoder}{chapter.1}% 12
\BOOKMARK [2][-]{subsection.1.6.1}{Samarbejde mellem QST og klinisk vurdering}{section.1.6}% 13
\BOOKMARK [1][-]{section.1.7}{Delkonklusion}{chapter.1}% 14
\BOOKMARK [0][-]{chapter.2}{Sikkerhed \(SAF\)}{}% 15
\BOOKMARK [1][-]{section.2.1}{Form\345l}{chapter.2}% 16
\BOOKMARK [1][-]{section.2.2}{HTA sp\370rgsm\345l}{chapter.2}% 17
\BOOKMARK [1][-]{section.2.3}{Metode}{chapter.2}% 18
\BOOKMARK [1][-]{section.2.4}{Patientsikkerhed}{chapter.2}% 19
\BOOKMARK [2][-]{subsection.2.4.1}{Sikkerhedsm\346ssige risici for patienter}{section.2.4}% 20
\BOOKMARK [1][-]{section.2.5}{Sikkerhedsforanstaltninger}{chapter.2}% 21
\BOOKMARK [2][-]{subsection.2.5.1}{Sikkerhedsforanstaltninger ved anvendelse af QST}{section.2.5}% 22
\BOOKMARK [1][-]{section.2.6}{Delkonklusion}{chapter.2}% 23
\BOOKMARK [0][-]{chapter.3}{Klinisk effekt \(EFF\)}{}% 24
\BOOKMARK [1][-]{section.3.1}{Form\345l}{chapter.3}% 25
\BOOKMARK [1][-]{section.3.2}{HTA sp\370rgsm\345l}{chapter.3}% 26
\BOOKMARK [1][-]{section.3.3}{Metode}{chapter.3}% 27
\BOOKMARK [1][-]{section.3.4}{Det nye kristine har skrevet }{chapter.3}% 28
\BOOKMARK [1][-]{section.3.5}{N\370jagtighed}{chapter.3}% 29
\BOOKMARK [2][-]{subsection.3.5.1}{Patientgruppering p\345 baggrund af QST-resultater}{section.3.5}% 30
\BOOKMARK [2][-]{subsection.3.5.2}{Repeterbarhed for QST}{section.3.5}% 31
\BOOKMARK [1][-]{section.3.6}{Delkonklusion}{chapter.3}% 32
\BOOKMARK [0][-]{chapter.4}{Omkostninger og \370konomisk evaluering \(ECO\)}{}% 33
\BOOKMARK [1][-]{section.4.1}{Form\345l}{chapter.4}% 34
\BOOKMARK [1][-]{section.4.2}{HTA sp\370rgsm\345l}{chapter.4}% 35
\BOOKMARK [1][-]{section.4.3}{Metode}{chapter.4}% 36
\BOOKMARK [1][-]{section.4.4}{Teknologiens effekt ift omkostninger}{chapter.4}% 37
\BOOKMARK [2][-]{subsection.4.4.1}{Produkt spefikke omkostninger}{section.4.4}% 38
\BOOKMARK [2][-]{subsection.4.4.2}{\330konomisk p\345virkning}{section.4.4}% 39
\BOOKMARK [2][-]{subsection.4.4.3}{Cost-effectiveness}{section.4.4}% 40
\BOOKMARK [1][-]{section.4.5}{Ressourceudnyttelse}{chapter.4}% 41
\BOOKMARK [2][-]{subsection.4.5.1}{Hvordan vil implementeringen af teknologien p\345virke regionens budget?}{section.4.5}% 42
\BOOKMARK [1][-]{section.4.6}{Sammendragning}{chapter.4}% 43
\BOOKMARK [0][-]{section*.13}{Litteratur}{}% 44
